Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer

Genitourinary Cancer

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

BJU Int

Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Baenziger O, Gibbs P, Tran B

doi: 10.1111/bju.15364

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Clin Genitourin Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S

doi: 10.1016/j.clgc.2017.08.020.

Genitourinary Cancer

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial

Prostate Cancer Prostatic Dis.

Martini A, Pfail J, Montorsi F, Galsky MD, Oh WK

doi: 10.1038/s41391-020-0231-5.

Genitourinary Cancer

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

doi: 10.1056/NEJMoa1704174.

Genitourinary Cancer

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

Lancet Oncol.

Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators.

doi: 10.1016/S1470-2045(19)30620-5.

Genitourinary Cancer

Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer

Clin Genitourin Cancer.

Miyake H, Hara T, Ozono S, Fujisawa M

doi: 10.1016/j.clgc.2016.07.005.

RECOMMENDED

Genitourinary Cancer

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era

Cancer Treat Rev.

Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G

doi: 10.1016/j.ctrv.2019.01.002.

RECOMMENDED

Genitourinary Cancer

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

N Engl J Med.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators.

doi: 10.1056/NEJMoa1903307.

RECOMMENDED

Genitourinary Cancer

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Lancet Oncol.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN

doi: 10.1016/S1470-2045(19)30082-8.

Related content

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial